{"Clinical Trial ID": "NCT00885755", "Intervention": ["INTERVENTION 1:", "Group A: Trastuzumab+Taxane/Capecitabine (6 weeks)", "In part 1 of the study, participants received a standard first-line treatment with trastuzumab and, at the clinician's discretion, either paclitaxel or docetaxel. Paclitaxel and docetaxel were administered according to one of the following regimens: docetaxel 75 mg/m2 or 100 mg/m2 3 weeks (if docetaxel-naive) or docetaxel 75 mg/m2 3 weeks (if docetaxel prior adjuvant) or docetaxel 60 mg/m2 3 weeks (if liver dysfunction due to metastatic intervention) or paclitaxel 80 mg/m2 weeks or 175 mg/m2 3 weeks (if docetaxel adjuvant) or docetaxel 60 mg/m2 3 weeks (if liver dysfunction due to metastatic intervention) or paclitaxel 80 mg/m2 or 175 mg/m2 3 weeks until the first progression of the disease.", "INTERVENTION 2:", "Group B: Trastuzumab+Taxane/ Capecitabine <6 weeks", "In part 1 of the study, participants received a standard first-line treatment with trastuzumab and, at the clinician's discretion, either paclitaxel or docetaxel. Paclitaxel and docetaxel were administered according to one of the following regimens: docetaxel 75 mg/m2 or 100 mg/m2 3 weeks (if docetaxel-naive) or docetaxel 75 mg/m2 3 weeks (if docetaxel prior adjuvant) or docetaxel 60 mg/m2 3 weeks (if liver dysfunction due to metastatic intervention) or paclitaxel 80 mg/m2 weeks or 175 mg/m2 3 weeks (if docetaxel adjuvant) or docetaxel 60 mg/m2 3 weeks (if metastatic intervention) or paclitaxel 80 mg/m2 or 175 mg/m2 3 weeks until the first progression of the disease."], "Eligibility": ["Incorporation criteria:", "Women, >=18 years of age;", "HER2-positive breast cancer;", "at least one metastatic site suitable for nucleus biopsy;", "Left ventricular ejection fraction > 50%.", "- Exclusion criteria:", "Previous adjuvant/neoadjuvant Herceptin in the last 6 months;", "Previous adjuvant taxan therapy in the last 12 months;", "The use of chemotherapy, immunotherapy or biological anticancer therapy in the last 3 weeks;", "Known haemorrhagic diatheses."], "Results": ["Performance measures:", "Part I: Progress-Free Survival (PFS) by Biomarker", "The progression was defined as an increase of at least 20 percent (%) in the lowest sum of the longest diameter (LDS) of lesions. The biomarkers studied: receptor 2 of the human epidermal growth factor p95 (p95HER2) positive (+ve) and negative (-ve), insulin-1 growth factor receptor (IGF1R) lower (<) median and greater or equal to ( ) median H membrane score, c-MET < median and median H membrane gene, homologous phosphatase and tensin (PTEN) homologous gene < median and median H cytoplasm, HER2 < median H membrane score, phosphatidylinositol-3-kinase catalytic subunit (PI3K) wild type (WT) and mutation (M) and gamma CF IIIa homozygotes Phenyl alanine (FF), heterozygote alanocin/Valine (VF) and homozygote (Hzygote) receptors", "Duration: End of the first 2 cycles (weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant's decision to stop treatment up to 46 months", "Results 1:", "Title of the arm/group: Group A: Trastuzumab+Taxane /Capecitabine (6 weeks)", "In part 1 of the study, participants received a standard first-line treatment with trastuzumab and, at the discretion of the clinician, either paclitaxel or docetaxel. Paclitaxel and docetaxel were administered in one of the following regimens: docetaxel 75 mg/m2 or 100 mg/m2 3 weeks (if docetaxel-na\u00efve) or docetaxel 75 mg/m2 3 weeks (if docetaxel adjuvant) or docetaxel 60 mg/m2 3 weeks (if liver dysfunction due to metastatic intervention) or paclitaxel 80 mg/m2 week or 175 mg/m2 3 weeks (if docetaxel adjuvant) or docetaxel 60 mg/m2 2 weeks (if liver dysfunction due to metastatic intervention) or paclitaxel 80 mg/m2 or 175 mg/m2 3 weeks (if docetaxel adjuvant) or docetaxel 60 mg/m2 2 weeks (if patient received a metastatic intervention) or paclitaxel 80 mg/m2 or 175 mg/m2 3 weeks (if docetaxel adjuvand'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd'd", "Total number of participants analysed: 27", "Median (95% confidence interval)", "Unit of measurement: month p95 HER2 +ve (n=9.0): NA [1] (3.384 to NA)", "P95 HER2 -ve (n=15.1): 13,963 (7.261 to 22.407)", "IRGF1R <median (n=12.0): 12.649 [1] (4.698 to NA)", "Median IRGF1R (n=14.1): 22.209 [1] (7.261 to NA)", "C-MET <median (n=10.1): 18.595 [1] (3.384 to NA)", "Median C-MET (n=15.0): 13,733 [1] (7.031 to NA)", "PTEN <median (n=12.0): 22.209 [1] (5,914 to NA)", "Average PTEN (n=14.1): 13,963 (6.37 to 31.179)", "- HER2 <median (n=11.1): 13,733 [1] (3.384 to NA)", "Median HER2 (n=14.0): 22.209 [1] (7.031 to NA)", "PI3K Amino acids WT (n=17.1): 13,848 [1] (7,261 to NA)", "PI3K Amino acids M (n=9.0): 22.407 [1] (4.698 to NA)", "CF Receiver Gamma IIIa F176V FF (n=9.0): 10.612 [1] (3.384 to NA)", "CF Receiver Gamma IIIa F176V VF (n=5.1): 11,335 [1] (9,528 to NA)", "CF Receiver Gamma IIIa F176V VV (n=4.0): 22.407 [1] (22.209 to NA)", "CF Receiver Gamma IIa R166H HH (n=3.0): NA [1] (9,528 to NA)", "CF Receiver Gamma IIa R166H HR (n=8.1): 22,209 [1] (3.384 to NA)", "CF Receiver Gamma IIa R166H RR (n=8.0): 13.963 [1] (5.914 to NA)", "CF Receiver Gamma IIb I232T II (n=12.1): 11,335 [1] (5,914 to NA)", "CF Receiver Gamma IIb I232T IT (n=1.0): NA [1] (NA to NA)", "CF Receiver Gamma IIb I232T TT (n=1.0): NA [1] (NA to NA)", "Results 2:", "Group B: Trastuzumab+Taxane/ Capecitabine <6 weeks", "In Part 1 of the study, participants were given standard first-line treatment with trastuzumab and, at the discretion of the clinician, either paclitaxel or docetaxel. Paclitaxel and docetaxel were given either as docetaxel 75 mg/m2 or 100 mg/m2 3 weeks (if docetaxel-na\u00efve) or docetaxel 75 mg/m2 3 weeks (if docetaxel adjuvant) or docetaxel 60 mg/m2 3 weeks (if liver dysfunction due to metastatic intervention) or paclitaxel 80 mg/m2 weeks or 175 mg/m2 3 weeks (if docetaxel adjuvant) or docetaxel 60 mg/m2 2 weeks (if liver dysfunction due to metastatic intervention) or paclitaxel 80 mg/m2 or 175 mg/m2 3 weeks (if docetaxel adjuvant) or docetaxel adjutaxel adjutaxel 60 mg/m2 2 weeks (if liver dysfunction due to metastatic intervention) or paclitaxel 80 mg/m2 or 175 mg/m2 3 weeks (if docetaxel adjub adjubit daily, or docetaxel adjubit, or adjubit, or adjutaxel 60 mg/ 2 weeks", "Total number of participants analysed: 1", "Median (95% confidence interval)", "Unit of measurement: month p95 HER2 +ve (n=9.0): NA [2] (NA to NA)", "P95 HER2 -ve (n=15.1): 1.216 [3] (NA to NA)", "IGF1R <median (n=12.0): NA [2] (NA to NA)", "Median IGF1R (n=14.1): 1,216 [3] (NA to NA)", "C-MET <median (n=10.1): 1.216 [3] (NA to NA)", "Median C-MET (n=15.0): NA [2] (NA to NA)", "PTEN <median (n=12.0): NA [2] (NA to NA)", "Average PTEN (n=14.1): 1,216 [3] (NA to NA)", "- HER2 <median (n=11.1): 1.216 [3] (NA to NA)", "Median HER2 (n=14.0): NA [2] (NA to NA)", "PI3K Amino acids WT (n=17.1): 1.216 [3] (NA to NA)", "PI3K Amino acids M (n=9.0): NA [2] (NA to NA)", "CF Receiver Gamma IIIa F176V FF (n=9.0): NA [2] (NA to NA)", "CF Receiver Gamma IIIa F176V VF (n=5.1): 1.216 [3] (NA to NA)", "CF Receiver Gamma IIIa F176V VV (n=4.0): NA [2] (NA to NA)", "CF Receiver Gamma IIa R166H HH (n=3.0): NA [2] (NA to NA)", "CF Receiver Gamma IIa R166H HR (n=8.1): 1.216 [3] (NA to NA)", "CF Receiver Gamma IIa R166H RR (n=8.0): NA [2] (NA to NA)", "CF Receiver Gamma IIb I232T II (n=12.1): 1.216 [3] (NA to NA)", "CF Receiver Gamma IIb I232T IT (n=1.0): NA [2] (NA to NA)", "CF Receiver Gamma IIb I232T TT (n=1.0): NA [2] (NA to NA)"], "Adverse Events": ["Undesirable Events 1:", "Total: 9/33 (27.27 per cent)", "Febrile neutropenia * 1/33 (3.03%)", "* 1/33 (3.03%)", "Pyrexia * 2/33 (6.06%)", "Chest pain * 1/33 (3.03%)", "* 1/33 (3.03%)", "Cellulite * 1/33 (3.03%)", "Sepsis * 1/33 (3.03%)", "- Hip fracture * 1/33 (3.03%)", "Back pain * 1/33 (3.03%)", "Menorrhagia * 1/33 (3.03%)", "Thrombosis * 1/33 (3.03%)", "Adverse Events 2:", "- Yeah, that's right."]}